Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies

We performed two phase I trials of the histone deacetylase inhibitor vorinostat combined with either the vascular endothelial growth factor inhibitor pazopanib (NCT01339871) or the proteasome inhibitor ixazomib (NCT02042989) in patients with metastatic TP53 mutant solid tumors. Both trials followed...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Sci Rep
Päätekijät: Wang, Yudong, Janku, Filip, Piha-Paul, Sarina, Hess, Kenneth, Broaddus, Russell, Liu, Lidong, Shi, Naiyi, Overman, Michael, Kopetz, Scott, Subbiah, Vivek, Naing, Aung, Hong, David, Tsimberidou, Apostolia M., Karp, Daniel, Yao, James, Fu, Siqing
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7033174/
https://ncbi.nlm.nih.gov/pubmed/32080210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-58366-z
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia